Article
The U.S. Food and Drug Administration questioned the effectiveness of a new cancer drug being developed by North Jersey-based Genta Inc. in a report released Friday, according to the Philadelphia Business Journal.
The Weekly Roundup: December 16-20
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Dermatology Times December 2024 Recap
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
How OJM Group Can Help Dermatologists Reach Their Financial Goals in 2025 and Beyond
Interview Intersection: Expert Interviews From December 2024